By Keytrice Castro, Business Development Specialist at Orbis Clinical
Risk-based quality management, RBQM, is not exactly new. The FDA pushed sponsors in this direction back in August 2013 with guidance on risk-based monitoring, encouraging companies to focus oversight on the most important risks to patient safety and clinical trial data quality instead of treating every site, process, and data point the same.¹
The FDA expanded on that in April 2023 with Q&A guidance on risk-based approaches to clinical investigation monitoring, including recommendations around monitoring plans, monitoring results, and sponsor oversight.² The FDA’s September 2025 adoption of ICH E6(R3) also reinforced quality by design, risk-based quality management, proportionality, and critical thinking across the clinical trial lifecycle.³
Taken together, the guidance points sponsors toward a more deliberate approach to clinical trial oversight: identify the risks that matter most, establish clear ownership, and ensure teams have the expertise to interpret and act on emerging signals.
That’s where RBQM becomes more than a regulatory or clinical operations shift. It becomes a talent strategy shift.
For many sponsors, the challenge now is translating a study’s specific risk profile into a workforce model. That requires determining which capabilities need to exist internally, which can sit with external partners, and where specialized clinical, data, biometrics, and quality expertise is needed to maintain effective oversight.
RBQM Is Only as Effective as the Team Behind It
A risk-based model is only as useful as the people managing it.
Dashboards, KRIs, centralized monitoring tools, and reports can all help identify potential issues.
Those tools still depend on experienced professionals who can interpret what the data is showing and determine the appropriate response.
Someone still has to ask:
- Is this signal meaningful?
- Does it impact patient safety?
- Could it affect data integrity?
- Does this need site-level action?
- Does this need vendor escalation?
- Could this become an inspection or submission issue later?
Answering those questions requires judgment that crosses traditional functional boundaries.
RBQM does not replace clinical operations, data management, biometrics, quality, or vendor oversight. It increases the need for those functions to work together, with clear accountability for how risks are identified, evaluated, escalated, and resolved.
Who Is Building Effective RBQM Models?
Organizations with more mature RBQM models typically establish clear internal ownership, even when significant portions of trial execution are outsourced.
They are not relying on a tool, a vendor report, or a monitoring plan. They have people who can interpret risk signals, challenge assumptions, and make decisions.
These teams often have:
- Clear ownership of who reviews, escalates, documents, and resolves issues
- Clinical operations leaders who understand risk-based oversight
- CTMs who know how to escalate issues early and appropriately
- Data and biometrics support to identify trends early
- Quality involvement throughout the clinical trial lifecycle
- Vendor oversight processes that keep external partners accountable
- A practical escalation model when risk signals require action
Clear ownership is critical because identifying a risk signal has limited value unless someone is accountable for determining its significance and driving the appropriate response.
As RBQM matures, workforce planning has to mature with it. Sponsors need people with the functional expertise and cross-functional judgment to make the model work in practice.
Where Lean Clinical Teams Can Face RBQM Gaps
RBQM can present a different challenge for small and emerging biotech companies. These organizations may understand the value and regulatory expectations surrounding risk-based oversight while operating with lean internal teams and limited specialized resources.
This is especially common in small and emerging biotech companies that are:
- Running only one or two studies
- Preparing for later-stage development for the first time
- Outsourcing heavily
- Operating without internal centralized monitoring expertise
- Missing dedicated data review, clinical quality, or vendor oversight support
Industry research shows the gap clearly. A Tufts CSDD study published in Therapeutic Innovation & Regulatory Science found that companies implemented RBQM in 57% of clinical trials on average. Adoption was lower among organizations conducting fewer than 25 trials annually, at 48%, compared with organizations conducting more than 100 trials annually, at 63%.⁴
Larger organizations often already have the infrastructure, systems, and cross-functional teams to support RBQM. Smaller sponsors may not, particularly when clinical operations, monitoring, data management, and quality activities are distributed across multiple external partners.
For lean sponsors, the workforce question becomes especially important: who inside the organization has enough visibility and expertise to connect information across those partners, evaluate emerging risks, and maintain meaningful sponsor oversight?
Small Biotechs Don’t Need a Large RBQM Department
For small biotech companies, the answer is not always hiring a full RBQM department.
Their trial volume, development stage, and available resources may not justify a large permanent team.
But relying entirely on external partners can leave sponsors too far removed from the decisions they are ultimately responsible for.
A more practical approach is to build the level of internal expertise that matches the company’s study portfolio, risk profile, outsourcing model, and stage of development.
That means looking at the study’s actual risk profile, then deciding what kind of talent is needed to manage it.
That may mean bringing in:
- An RBQM consultant to establish the framework
- A clinical operations leader with risk-based oversight experience
- A CTM who understands escalation and vendor oversight
- A clinical data review specialist
- A biostatistics or statistical programming resource for KRIs and reporting
- A GCP quality consultant to support inspection readiness
- A fractional clinical quality or RBQM lead
Depending on the program, these capabilities may come from permanent employees, contractors, consultants, fractional experts, or a combination of internal and external resources. The appropriate model depends on what the sponsor needs to own and where additional expertise will have the greatest impact.
The New Hiring Question: Who Translates Risk into Action?
RBQM creates a translation challenge.
A protocol may have scientific complexity. A study may have operational risk. A program may have data integrity, vendor oversight, or inspection-readiness concerns. But those risks do not automatically tell a company who to hire.
That is where talent strategy matters.
A sponsor experiencing monitoring challenges, for example, may initially assume it needs additional CRAs. A closer look at the underlying risk could point instead to a need for stronger CTM leadership, centralized monitoring expertise, clinical data review, vendor oversight, or quality support.
This is why RBQM can change workforce planning well beyond clinical monitoring. The more useful hiring question is which capabilities are needed to understand the study’s risks, identify meaningful signals, and ensure the right people can act on them.
For life sciences companies, this creates an opportunity to align hiring decisions more closely with the science, study design, operational model, and regulatory demands of the program rather than relying on standardized staffing assumptions.
How Orbis Clinical Can Help
RBQM hiring is not one-size-fits-all. A Phase I startup, a lean sponsor preparing for Phase III, and a commercial-stage company managing multiple studies will not need the same team.
Orbis Clinical helps life sciences companies build practical, right-sized teams around their stage, study complexity, and internal infrastructure.
Our clinical staffing approach starts with understanding the program itself: where the sponsor has internal expertise, which responsibilities sit with CROs or other vendors, where oversight gaps exist, and which risks require additional specialized support. From there, we can help determine the experience and engagement model that best fits the need.
For companies implementing or strengthening RBQM, that may include support across:
- RBQM consulting
- Centralized monitoring
- Clinical operations leadership
- Clinical trial management
- Vendor oversight
- Clinical data management
- Biostatistics and statistical programming
- GCP quality and inspection readiness
- Contract, contract-to-hire, permanent, or fractional talent
Whether a company is building an RBQM framework for the first time, preparing for later-stage development, strengthening internal oversight, or closing gaps ahead of inspection or submission, Orbis can help identify the specialized talent needed to make risk-based oversight practical and scalable.
As risk-based approaches become more deeply embedded in clinical development, sponsors will need to evaluate their workforce with the same discipline they apply to study risk. The right clinical staffing model gives teams access to the expertise they need at the point it is needed, while preserving the internal ownership and oversight regulators expect.
If your clinical development program has gaps in RBQM, clinical operations, data and biometrics, or clinical quality, Orbis Clinical can help you assess the expertise you need and build a staffing model around your program. Contact our team to discuss your clinical staffing needs.
About the Author
Keytrice Castro is a dynamic Business Development Specialist at Orbis Clinical, bringing a sales background in medical devices and telecom, along with recruitment expertise in biotech, pharma, and healthcare. Passionate about disruptive technologies, AI-driven drug discovery, and precision medicine, she thrives on building meaningful relationships that drive business growth in the life sciences sector. Known for her strategic and personable approach, Keytrice helps organizations navigate tight timelines and scale their teams effectively. Beyond work, she is a dedicated advocate for kidney donation, having been a living donor to a friend with IgA nephropathy.
Sources
¹ FDA, “Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring,” Guidance for Industry, August 2013.
² FDA, “A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers,” Guidance for Industry, April 2023.
³ FDA, “E6(R3) Good Clinical Practice,” Guidance for Industry, September 2025.
⁴ Dirks, A., Florez, M., Torche, F., Young, S., Slizgi, B., & Getz, K. “Comprehensive Assessment of Risk-Based Quality Management Adoption in Clinical Trials.” Therapeutic Innovation & Regulatory Science, 58, 520–527, 2024.